EGFR-Targeted TKIs Continue to Have Outsized Impact in NSCLC

Thomas J. Lynch Jr, MD, details how treatments are evolving for patients with EGFR-mutated advanced non–small cell lung cancer.

Related Keywords

Washington ,United States ,Seattle ,Hollywood ,California ,Lynch Jr ,Thomasj Lynch Jr ,Fred Hutch Cancer Center ,Winter Lung Cancer ,Raisbeck Endowed Chair ,Lung Cancer ,Amivantamab Treating Exon ,Examining Osimertinib ,Cancer Care Lecture ,Winter Lung Cancer Conference ,D ,Patients With Egfr Mutated Advanced Non Small Cell Lung Cancer ,